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The claimed ability of non-steroidal antiandrogens to preserve libido and sexual potency is sought as a potential improvement in the palliative management of prostate cancer. A critical issue for the clinical use of these compounds is, however, the reported evidence in the rat of an excessive increase in testosterone concentrations as a consequence of the androgen negative feedback interruption. On the other hand, the recovery of testicular function after long-term inhibition by luteinizing hormone\x=req-\ releasing hormone (LHRH) analogs is also an important concern in view of the proposed use of these compounds for the treatment of several non-malignant conditions. We addressed these issues by studying the long-term endocrine effects induced by the administration of either the non-steroidal antiandrogen nilutamide or the depot preparation of d-Trp6-LHRH in men with prostate cancer. Treatment with the antiandrogen induced a marked increase in gonadotropin levels, LH concentrations rising from a mean (sem) of 17.5\m=+-\1.6to a maximum of 56.6\m=+-\6.9kU/l (p<0.001), while mean testosterone and 17\g=b\ estradiol-concentrations rose only by about 50% and 70% over pretreatment values, testosterone levels reaching a plateau after 1 month of treatment. In the subjects treated with the LHRH agonist, 6 months after discontinuation of long-term administration the mean (\m=+-\sem)LH had risen to 36.9 \ m=+-\ 6.8 IU/l while mean testosterone levels were still as low as 1.7 \ m=+-\ 0.7 and rose only to a maximum of 4.2 \m=+-\1 nmol/l after high-dose human chorionic gonadotropin loadings. We conclude that in elderly men with prostate cancer: (i) stimulation of the entire axis by non-steroidal antiandrogens induces only a mild testosterone increase, the testis being the site of the reduced response; (ii) antiandrogen but they were inhibited significantly by the LHRH analog.
The stimulation test with exogenous GnRH is shown in Fig. 2 advanced prostatic cancer (4, 10, 11 (12) . While the difference in basal and stimulated LH concentrations may reflect both the age-related increase in the gonadotropin-suppressive effect of androgens (with consequent increased responsiveness to its interruption) (13) (14) .
As regards the pattern of gonadal effects, the sustained LH elevation induced by the antiandrogen elicited a selective blockade of 17, 20-desmolase, as inferred by the decreased androstenedione/17-OHP ratio. This defect of the "late" steroidogenic pathway, which distinguishes the process of gonadal desensitization, is attributed to an estrogen-mediated action (15 
